Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb ...

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation ...

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

Moderna (MRNA) stock is in focus as BioNTech (BNTX) sues the biotech for allegedly violating patent linked to the rival shot developed with Pfizer (PFE). Read more here.

BioNTech has filed a lawsuit against Moderna in a Delaware federal court, claiming infringement on a patent related to their COVID-19 vaccine technology. Moderna's vaccine, mNEXSPIKE, allegedly ...

The pharmaceutical industry is not the enemy,” writes Richard Hughes IV, who was Moderna’s VP for public policy when the Covid vaccine rolled out.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...